methylation
Previse Launches Esophageal Cancer Risk Test, Raises $3M to Support Commercial Expansion
The company hopes to build prospective clinical utility evidence for the Esopredict test, its first clinical assay, to support future reimbursement.
Tempus, Actuate Therapeutics Ink Collaboration to Discover Biomarkers of Response for Elraglusib
Tempus will provide its clinical xF+ liquid biopsy and research-use-only DNA methylation tests to the ongoing Phase I/II trial of Actuate's GSK-3β inhibitor elraglusib.
The Canadian company plans to test the clinical utility of its targeted 90-marker panel in monitoring patient response to therapy.
Esophageal Cancer Molecular Study Highlights Tumor Subtypes, Treatment Response Markers
Researchers found four esophageal squamous cell carcinoma molecular subtypes by generating genomic, transcriptomic, epigenetic, and proteomic profiles for more than 150 cases.
Multiomic Study Points to New Colorectal Cancer Risk Contributors
Researchers tracked down more than 100 new risk variants with a combination of genomic, transcriptomic, and methylation analyses, highlighting new and known risk pathways.